Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV.

Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C.

Antivir Ther. 2019 Jul 30. doi: 10.3851/IMP3327. [Epub ahead of print]

PMID:
31359874
2.

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).

Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, Husson J, Chua J, Price A, Mathur P, Rosenthal E, Kattakuzhy S, Masur H, Kottilil S.

J Hepatol. 2019 Sep;71(3):498-504. doi: 10.1016/j.jhep.2019.05.021. Epub 2019 Jun 5.

PMID:
31173815
3.

Opioids and Infectious Diseases: A Converging Public Health Crisis.

Schwetz TA, Calder T, Rosenthal E, Kattakuzhy S, Fauci AS.

J Infect Dis. 2019 Jul 2;220(3):346-349. doi: 10.1093/infdis/jiz133.

PMID:
30941402
4.

Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.

Chaudhury CS, Mee T, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Stanley TL, Hadigan C.

Clin Infect Dis. 2019 Feb 2. doi: 10.1093/cid/ciy965. [Epub ahead of print]

PMID:
30715229
5.

Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns.

Abutaleb A, Kattakuzhy S, Kottilil S, O'Connor E, Wilson E.

J Neurovirol. 2018 Dec;24(6):670-678. doi: 10.1007/s13365-018-0678-5. Epub 2018 Oct 5. Review.

6.

Implementation of a unique hepatitis C care continuum model in Rwanda.

Mathur P, Comstock E, Makuza JD, Emmanuel B, Sebeza J, Kiromera A, Wilson E, Kattakuzhy S, Nelson A, Kottilil S, Riedel DJ.

J Public Health (Oxf). 2019 Jun 1;41(2):e203-e208. doi: 10.1093/pubmed/fdy115.

PMID:
29982813
7.

Expansion of Treatment for Hepatitis C Virus Infection.

Emmanuel B, Masur H, Kottilil S, Kattakuzhy S.

Ann Intern Med. 2018 Mar 20;168(6):457-459. doi: 10.7326/L17-0698. No abstract available.

PMID:
29554678
8.

Time to end treatment restrictions for people with hepatitis C who inject drugs.

Rosenthal ES, Kattakuzhy S, Kottilil S.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):142-143. doi: 10.1016/S2468-1253(18)30001-3. Epub 2018 Jan 6. No abstract available.

PMID:
29310927
9.

No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.

Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy S, Rosenthal E, Kottilil S, Masur H, Hadigan C.

J Infect Dis. 2017 Dec 27;217(1):47-50. doi: 10.1093/infdis/jix517.

10.

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers.

Ann Intern Med. 2017 Sep 5;167(5):311-318. doi: 10.7326/M17-0118. Epub 2017 Aug 8.

11.

A Practical Approach and Model of Care for HCV Treatment With Direct Acting Antivirals in an Urban Setting.

Akoth E, Gross C, Silk R, Rosenthal E, Kattakuzhy S.

J Assoc Nurses AIDS Care. 2017 Sep - Oct;28(5):680-684. doi: 10.1016/j.jana.2017.04.007. Epub 2017 Apr 26. No abstract available.

PMID:
28506435
12.

Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment.

Tang LS, Masur J, Sims Z, Nelson A, Osinusi A, Kohli A, Kattakuzhy S, Polis M, Kottilil S.

World J Hepatol. 2016 Nov 8;8(31):1318-1326.

13.

Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S.

Clin Microbiol Rev. 2017 Jan;30(1):23-42. Epub 2016 Oct 19. Review.

14.

Hepatitis C genotype 3 disease.

Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S.

Hepatol Int. 2016 Nov;10(6):861-870. Epub 2016 Jun 21. Review.

PMID:
27328848
15.

HIV/HCV Co-infection: Overcoming Barriers to Treatment.

Gross C, Akoth E, Price A, Kattakuzhy S, Silk R, Rosenthal E.

J Assoc Nurses AIDS Care. 2016 Jul-Aug;27(4):524-9. doi: 10.1016/j.jana.2016.02.009. Epub 2016 Feb 20.

PMID:
26996983
16.

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S.

Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24.

PMID:
26595450
17.

Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.

Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S.

Expert Rev Gastroenterol Hepatol. 2016;10(1):21-36. doi: 10.1586/17474124.2016.1119042. Epub 2015 Dec 11. Review.

PMID:
26558305
18.

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S.

Clin Infect Dis. 2016 Feb 1;62(3):280-288. doi: 10.1093/cid/civ874. Epub 2015 Oct 31.

19.

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S.

Clin Infect Dis. 2016 Feb 15;62(4):440-447. doi: 10.1093/cid/civ897. Epub 2015 Oct 26.

20.

Sofosbuvir for treatment of chronic hepatitis C.

Kattakuzhy S, Levy R, Kottilil S.

Hepatol Int. 2015 Apr;9(2):161-73. doi: 10.1007/s12072-014-9606-9. Epub 2015 Jan 28. Review.

PMID:
25788194
21.

Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus.

Hadigan C, Kattakuzhy S.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):685-96. doi: 10.1016/j.ecl.2014.05.003. Review.

22.

Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as acute appendicitis in an HIV-infected patient.

Faldetta KF, Kattakuzhy S, Wang HW, Sereti I, Sheikh V.

BMC Infect Dis. 2014 Jun 9;14:313. doi: 10.1186/1471-2334-14-313.

Supplemental Content

Loading ...
Support Center